Tags: Allergies | hives | itching | omalizumab | novartis

New Medication Effective Against Chronic Hives

Sunday, 06 Oct 2013 10:10 AM

Swiss drugmaker Novartis said on Saturday its drug omalizumab was almost doubly effective in improving quality of life for patients with a severe form of hives, compared with a placebo, according to a late-stage study.

The third and final late-stage study of omalizumab for treating the skin disease chronic spontaneous urticaria (CSU) found the drug was nearly twice as effective versus a placebo in improving life quality within 12 weeks of treatment, while also significantly reducing itch and hives caused by the condition.

Novartis said it had filed applications for the approval of omalizumab for treating patients with CSU to U.S. and European Union health authorities in the third quarter.
 
Omalizumab, which is also known as Xolair, is already approved for treating severe asthma.

© 2015 Thomson/Reuters. All rights reserved.

1Like our page
2Share
Health-News
Swiss drugmaker Novartis said on Saturday its drug omalizumab was almost doubly effective in improving quality of life for patients with a severe form of hives, compared with a placebo, according to a late-stage study. The third and final late-stage study of omalizumab for...
hives,itching,omalizumab,novartis
124
2013-10-06
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved